- Home
- GILD vs SMFG Comparison
GILD vs SMFG Comparison
Compare GILD & SMFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- SMFG
- Stock Information
- Founded
- GILD 1987
- SMFG 2002
- Country
- GILD United States
- SMFG Japan
- Employees
- GILD N/A
- SMFG N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- SMFG Commercial Banks
- Sector
- GILD Health Care
- SMFG Finance
- Exchange
- GILD Nasdaq
- SMFG Nasdaq
- Market Cap
- GILD 113.0B
- SMFG 97.7B
- IPO Year
- GILD 1992
- SMFG 1949
- Fundamental
- Price
- GILD $92.28
- SMFG $14.18
- Analyst Decision
- GILD Buy
- SMFG
- Analyst Count
- GILD 26
- SMFG 0
- Target Price
- GILD $96.71
- SMFG N/A
- AVG Volume (30 Days)
- GILD 6.4M
- SMFG 984.4K
- Earning Date
- GILD 02-11-2025
- SMFG 01-30-2025
- Dividend Yield
- GILD 3.38%
- SMFG 2.87%
- EPS Growth
- GILD N/A
- SMFG 62.30
- EPS
- GILD 0.10
- SMFG 1.90
- Revenue
- GILD $28,299,000,000.00
- SMFG $29,024,781,023.00
- Revenue This Year
- GILD $6.54
- SMFG N/A
- Revenue Next Year
- GILD N/A
- SMFG $6.26
- P/E Ratio
- GILD $937.76
- SMFG $12.68
- Revenue Growth
- GILD 3.31
- SMFG 12.07
- 52 Week Low
- GILD $62.07
- SMFG $9.23
- 52 Week High
- GILD $98.90
- SMFG $15.56
- Technical
- Relative Strength Index (RSI)
- GILD 52.30
- SMFG 44.06
- Support Level
- GILD $90.27
- SMFG $13.96
- Resistance Level
- GILD $93.59
- SMFG $15.02
- Average True Range (ATR)
- GILD 2.12
- SMFG 0.17
- MACD
- GILD -0.21
- SMFG -0.17
- Stochastic Oscillator
- GILD 50.91
- SMFG 6.79
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About SMFG Sumitomo Mitsui Financial Group Inc Unsponsored (Japan)
Sumitomo Mitsui Financial Group is roughly tied with Mizuho Financial Group for the status of Japan's second-largest bank after Mitsubishi UFJ Financial Group. As of March 2024, its market share of domestic loans was 7.2%, compared with 8.0% for MUFG. It has a larger consumer finance business than the other two megabanks, owning 100% of the Promise business and SMBC Card. It also controls one of Japan's largest leasing companies and SMBC Aviation Capital, one of the top five aircraft lessors globally. In securities, its SMBC Nikko unit is Japan's third-largest retail broker, although SMFG has lagged somewhat in institutional securities business and asset management.